AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. UTHR
  4. [S-8] United Therapeutics Corp Employee Benefit Plan Registration

[S-8] United Therapeutics Corp Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

United Therapeutics Corp. (UTHR) has filed a Form S-8 to register 950,000 additional common shares (par $0.01) for issuance under its Amended & Restated 2015 Stock Incentive Plan. The company relies on General Instruction E, incorporating eight prior S-8 filings that together registered 13,820,000 shares; cumulative authorization for the plan now totals 14,770,000 shares. UTHR is incorporated in Delaware, qualifies as a large accelerated filer, and lists its principal executive offices in Silver Spring, MD.

The filing, signed by Chair & CEO Martine A. Rothblatt on 30 July 2025, contains standard exhibits such as the counsel opinion, auditor consent, and plan document. No financial statements, earnings data, or new corporate events are included; the registration strictly facilitates future equity compensation grants.

United Therapeutics Corp. (UTHR) ha presentato un modulo Form S-8 per registrare 950.000 azioni ordinarie aggiuntive (valore nominale $0,01) da emettere nell'ambito del suo Piano di Incentivi Azionari Modificato e Ristabilito del 2015. L'azienda si basa sull'Istruzione Generale E, che incorpora otto precedenti registrazioni S-8 che complessivamente hanno registrato 13.820.000 azioni; l'autorizzazione cumulativa per il piano ora ammonta a 14.770.000 azioni. UTHR 猫 costituita nel Delaware, 猫 qualificata come large accelerated filer e ha la sede principale a Silver Spring, MD.

La documentazione, firmata dalla Presidente e CEO Martine A. Rothblatt il 30 luglio 2025, include allegati standard come il parere legale, il consenso del revisore e il documento del piano. Non sono inclusi bilanci, dati sugli utili o nuovi eventi societari; la registrazione serve esclusivamente a facilitare future assegnazioni di compensi azionari.

United Therapeutics Corp. (UTHR) ha presentado un Formulario S-8 para registrar 950,000 acciones comunes adicionales (valor nominal $0.01) para su emisi贸n bajo su Plan de Incentivos de Acciones Modificado y Restablecido de 2015. La compa帽铆a se basa en la Instrucci贸n General E, que incorpora ocho presentaciones previas de S-8 que en conjunto registraron 13,820,000 acciones; la autorizaci贸n acumulada para el plan ahora suma 14,770,000 acciones. UTHR est谩 incorporada en Delaware, califica como large accelerated filer y tiene sus oficinas principales en Silver Spring, MD.

La presentaci贸n, firmada por la Presidenta y CEO Martine A. Rothblatt el 30 de julio de 2025, contiene anexos est谩ndar como la opini贸n legal, el consentimiento del auditor y el documento del plan. No se incluyen estados financieros, datos de ganancias ni nuevos eventos corporativos; el registro facilita exclusivamente futuras concesiones de compensaci贸n en acciones.

United Therapeutics Corp. (UTHR)電� 2015雲� 臧滌爼 氚� 鞛檿鞚鸽悳 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 950,000欤� 於旉皜 氤错喌欤� (鞎‰┐臧� $0.01)毳� 霌彪頃橁赴 鞙勴暣 Form S-8鞚� 鞝滌稖頄堨姷雼堧嫟. 須岇偓電� 齑� 13,820,000欤茧ゼ 霌彪頃� 8瓯挫潣 鞚挫爠 S-8 鞝滌稖鞚� 韽暔頃橂姅 鞚茧皹 歆�旃� E毳� 攴缄卑搿� 頃橂┌, 瓿勴殟鞐� 雽�頃� 雸勳爜 鞀轨澑 欤检嫕 靾橂姅 順勳灛 14,770,000欤�鞐� 鞚措雼堧嫟. UTHR電� 雿鸽澕鞗柎鞐� 靹る霅橃棃鞙茧┌, 雽�順� 臧�靻� 鞝滌稖鞛�搿� 攵勲霅橁碃 氤胳偓電� 氅旊Υ霝滊摐欤� 鞁る矂鞀ろ攧毵侅棎 鞙勳箻頃� 鞛堨姷雼堧嫟.

2025云� 7鞗� 30鞚�鞐� 須岇灔 瓴� CEO鞚� Martine A. Rothblatt臧� 靹滊獏頃� 鞚措矆 鞝滌稖 氍胳劀鞐愲姅 氩曤 鞚橁铂靹�, 臧愳偓鞚� 霃欖潣靹�, 瓿勴殟 氍胳劀 霌� 響滌 攵�搿濎澊 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞛鞝滍憸, 靾橃澋 雿办澊韯�, 鞁犼窚 旮办梾 鞚措菠韸鸽姅 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 鞚措矆 霌彪鞚� 頄ロ泟 欤检嫕 氤挫儊 攵�鞐ゼ 鞙勴暅 鞝堨皑毳� 歆�鞗愴晿電� 雿� 氇╈爜鞚� 鞛堨姷雼堧嫟.

United Therapeutics Corp. (UTHR) a d茅pos茅 un formulaire S-8 pour enregistrer 950 000 actions ordinaires suppl茅mentaires (valeur nominale de 0,01 $) 脿 茅mettre dans le cadre de son Plan d'incitation en actions modifi茅 et r茅vis茅 de 2015. La soci茅t茅 s'appuie sur l'Instruction g茅n茅rale E, incorporant huit d茅p么ts S-8 ant茅rieurs ayant enregistr茅 au total 13 820 000 actions ; l'autorisation cumulative du plan atteint d茅sormais 14 770 000 actions. UTHR est constitu茅e dans le Delaware, est qualifi茅e de large accelerated filer et a son si猫ge principal 脿 Silver Spring, MD.

Le d茅p么t, sign茅 par la pr茅sidente et PDG Martine A. Rothblatt le 30 juillet 2025, comprend des annexes standard telles que l'avis du conseil juridique, le consentement de l'auditeur et le document du plan. Aucun 茅tat financier, donn茅es de r茅sultats ou nouvel 茅v茅nement d'entreprise n'est inclus ; l'enregistrement facilite strictement les futures attributions de r茅mun茅rations en actions.

United Therapeutics Corp. (UTHR) hat ein Formular S-8 eingereicht, um 950.000 zus盲tzliche Stammaktien (Nennwert $0,01) zur Ausgabe im Rahmen seines ge盲nderten und neu gefassten Aktienanreizplans von 2015 zu registrieren. Das Unternehmen st眉tzt sich auf die Allgemeine Anweisung E, die acht fr眉here S-8-Einreichungen einbezieht, die zusammen 13.820.000 Aktien registriert haben; die kumulative Autorisierung f眉r den Plan bel盲uft sich nun auf 14.770.000 Aktien. UTHR ist in Delaware eingetragen, qualifiziert sich als large accelerated filer und hat seinen Hauptsitz in Silver Spring, MD.

Die Einreichung, unterzeichnet von Vorstandsvorsitzender und CEO Martine A. Rothblatt am 30. Juli 2025, enth盲lt Standardanh盲nge wie die Rechtsgutachten, die Zustimmung des Wirtschaftspr眉fers und das Plan-Dokument. Es sind keine Finanzberichte, Gewinnzahlen oder neue Unternehmensereignisse enthalten; die Registrierung dient ausschlie脽lich der Erm枚glichung zuk眉nftiger Aktienverg眉tungen.

Positive
  • Maintains competitive equity compensation pool, supporting talent retention and alignment with shareholders.
Negative
  • Adds potential dilution of up to 950,000 shares if fully issued and vested.

Insights

TL;DR: Routine S-8 adds 950k shares to incentive plan; immaterial but marginally dilutive.

The filing merely extends the share pool available for employee and director equity awards. With 14.8 million shares now registered since 2015, the company signals continued reliance on stock-based compensation for retention and alignment. Because S-8 shares come from authorized stock, actual dilution depends on future grant pacing and vesting. Absent accompanying financial updates, the action is procedural, carrying negligible immediate valuation impact.

TL;DR: Governance-neutral filing; updates plan without changing control or board structure.

Registering additional shares under an existing, shareholder-approved plan is standard practice. The company preserves transparency by incorporating earlier filings and providing legal opinions. No amendments to charter or bylaws are proposed, and the board composition remains unchanged. Investors should monitor cumulative dilution over time, but this single 950k-share addition is modest relative to UTHR鈥檚 market cap.

United Therapeutics Corp. (UTHR) ha presentato un modulo Form S-8 per registrare 950.000 azioni ordinarie aggiuntive (valore nominale $0,01) da emettere nell'ambito del suo Piano di Incentivi Azionari Modificato e Ristabilito del 2015. L'azienda si basa sull'Istruzione Generale E, che incorpora otto precedenti registrazioni S-8 che complessivamente hanno registrato 13.820.000 azioni; l'autorizzazione cumulativa per il piano ora ammonta a 14.770.000 azioni. UTHR 猫 costituita nel Delaware, 猫 qualificata come large accelerated filer e ha la sede principale a Silver Spring, MD.

La documentazione, firmata dalla Presidente e CEO Martine A. Rothblatt il 30 luglio 2025, include allegati standard come il parere legale, il consenso del revisore e il documento del piano. Non sono inclusi bilanci, dati sugli utili o nuovi eventi societari; la registrazione serve esclusivamente a facilitare future assegnazioni di compensi azionari.

United Therapeutics Corp. (UTHR) ha presentado un Formulario S-8 para registrar 950,000 acciones comunes adicionales (valor nominal $0.01) para su emisi贸n bajo su Plan de Incentivos de Acciones Modificado y Restablecido de 2015. La compa帽铆a se basa en la Instrucci贸n General E, que incorpora ocho presentaciones previas de S-8 que en conjunto registraron 13,820,000 acciones; la autorizaci贸n acumulada para el plan ahora suma 14,770,000 acciones. UTHR est谩 incorporada en Delaware, califica como large accelerated filer y tiene sus oficinas principales en Silver Spring, MD.

La presentaci贸n, firmada por la Presidenta y CEO Martine A. Rothblatt el 30 de julio de 2025, contiene anexos est谩ndar como la opini贸n legal, el consentimiento del auditor y el documento del plan. No se incluyen estados financieros, datos de ganancias ni nuevos eventos corporativos; el registro facilita exclusivamente futuras concesiones de compensaci贸n en acciones.

United Therapeutics Corp. (UTHR)電� 2015雲� 臧滌爼 氚� 鞛檿鞚鸽悳 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 950,000欤� 於旉皜 氤错喌欤� (鞎‰┐臧� $0.01)毳� 霌彪頃橁赴 鞙勴暣 Form S-8鞚� 鞝滌稖頄堨姷雼堧嫟. 須岇偓電� 齑� 13,820,000欤茧ゼ 霌彪頃� 8瓯挫潣 鞚挫爠 S-8 鞝滌稖鞚� 韽暔頃橂姅 鞚茧皹 歆�旃� E毳� 攴缄卑搿� 頃橂┌, 瓿勴殟鞐� 雽�頃� 雸勳爜 鞀轨澑 欤检嫕 靾橂姅 順勳灛 14,770,000欤�鞐� 鞚措雼堧嫟. UTHR電� 雿鸽澕鞗柎鞐� 靹る霅橃棃鞙茧┌, 雽�順� 臧�靻� 鞝滌稖鞛�搿� 攵勲霅橁碃 氤胳偓電� 氅旊Υ霝滊摐欤� 鞁る矂鞀ろ攧毵侅棎 鞙勳箻頃� 鞛堨姷雼堧嫟.

2025云� 7鞗� 30鞚�鞐� 須岇灔 瓴� CEO鞚� Martine A. Rothblatt臧� 靹滊獏頃� 鞚措矆 鞝滌稖 氍胳劀鞐愲姅 氩曤 鞚橁铂靹�, 臧愳偓鞚� 霃欖潣靹�, 瓿勴殟 氍胳劀 霌� 響滌 攵�搿濎澊 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞛鞝滍憸, 靾橃澋 雿办澊韯�, 鞁犼窚 旮办梾 鞚措菠韸鸽姅 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 鞚措矆 霌彪鞚� 頄ロ泟 欤检嫕 氤挫儊 攵�鞐ゼ 鞙勴暅 鞝堨皑毳� 歆�鞗愴晿電� 雿� 氇╈爜鞚� 鞛堨姷雼堧嫟.

United Therapeutics Corp. (UTHR) a d茅pos茅 un formulaire S-8 pour enregistrer 950 000 actions ordinaires suppl茅mentaires (valeur nominale de 0,01 $) 脿 茅mettre dans le cadre de son Plan d'incitation en actions modifi茅 et r茅vis茅 de 2015. La soci茅t茅 s'appuie sur l'Instruction g茅n茅rale E, incorporant huit d茅p么ts S-8 ant茅rieurs ayant enregistr茅 au total 13 820 000 actions ; l'autorisation cumulative du plan atteint d茅sormais 14 770 000 actions. UTHR est constitu茅e dans le Delaware, est qualifi茅e de large accelerated filer et a son si猫ge principal 脿 Silver Spring, MD.

Le d茅p么t, sign茅 par la pr茅sidente et PDG Martine A. Rothblatt le 30 juillet 2025, comprend des annexes standard telles que l'avis du conseil juridique, le consentement de l'auditeur et le document du plan. Aucun 茅tat financier, donn茅es de r茅sultats ou nouvel 茅v茅nement d'entreprise n'est inclus ; l'enregistrement facilite strictement les futures attributions de r茅mun茅rations en actions.

United Therapeutics Corp. (UTHR) hat ein Formular S-8 eingereicht, um 950.000 zus盲tzliche Stammaktien (Nennwert $0,01) zur Ausgabe im Rahmen seines ge盲nderten und neu gefassten Aktienanreizplans von 2015 zu registrieren. Das Unternehmen st眉tzt sich auf die Allgemeine Anweisung E, die acht fr眉here S-8-Einreichungen einbezieht, die zusammen 13.820.000 Aktien registriert haben; die kumulative Autorisierung f眉r den Plan bel盲uft sich nun auf 14.770.000 Aktien. UTHR ist in Delaware eingetragen, qualifiziert sich als large accelerated filer und hat seinen Hauptsitz in Silver Spring, MD.

Die Einreichung, unterzeichnet von Vorstandsvorsitzender und CEO Martine A. Rothblatt am 30. Juli 2025, enth盲lt Standardanh盲nge wie die Rechtsgutachten, die Zustimmung des Wirtschaftspr眉fers und das Plan-Dokument. Es sind keine Finanzberichte, Gewinnzahlen oder neue Unternehmensereignisse enthalten; die Registrierung dient ausschlie脽lich der Erm枚glichung zuk眉nftiger Aktienverg眉tungen.


As filed with the Securities and Exchange Commission on July 30, 2025
Registration No. 333-    
     
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________

FORM S-8

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

United Therapeutics Corporation
(Exact Name of Registrant as Specified in the Charter)

Delaware52-1984749
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

1000 Spring Street
Silver Spring, MD

20910
(Address of principal executive offices)(Zip Code)

UNITED THERAPEUTICS CORPORATION
AMENDED AND RESTATED
2015 STOCK INCENTIVE PLAN
(Full title of the plan)

Paul A. Mahon, Executive Vice President and General Counsel
United Therapeutics Corporation
1000 Spring Street
Silver Spring, MD 20910
(301) 608-9292
(Name, address and telephone number, including area code, of agent for service)

Copy to:

Stephen I. Glover, Esq.
Gibson, Dunn & Crutcher LLP
1700 M Street, N.W.
Washington, D.C. 20036
(202) 955-8500
John S. Hess, Jr., Esq.
Executive Vice President and Deputy General Counsel
United Therapeutics Corporation
1735 Connecticut Avenue, N.W.
Washington, D.C. 20009
(202) 483-7000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


INTRODUCTION

This Registration Statement on Form S-8 is being filed by United Therapeutics Corporation, a Delaware public benefit corporation (the “Company” or the “Registrant”), in accordance with General Instruction E to Form S-8 relating to 950,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), issuable to eligible individuals under the Company’s Amended and Restated 2015 Stock Incentive Plan, which 950,000 shares are in addition to (a) 6,150,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-205309) filed with the Securities and Exchange Commission on June 29, 2015, (b) 2,900,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-225942) filed with the Securities and Exchange Commission on June 28, 2018, (c) 450,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-232906) filed with the Securities and Exchange Commission on July 31, 2019, (d) 500,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-240156) filed with the Securities and Exchange Commission on July 29, 2020, (e) 1,000,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-258434) filed with the Securities and Exchange Commission on August 4, 2021, (f) 500,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-266478) filed with the Securities and Exchange Commission on August 3, 2022, (g) 1,000,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-273590) filed with the Securities and Exchange Commission on August 2, 2023, and (h) 1,320,000 shares of Common Stock previously registered on the Registrant’s Registration Statement on Form S-8 (No. 333-281117) filed with the Securities and Exchange Commission on July 31, 2024, in each case together with all exhibits filed therewith or incorporated therein by reference ((a), (b), (c), (d), (e), (f), (g), and (h) collectively, the “Prior Registration Statements”). Except as supplemented by the information set forth herein, the contents of the Prior Registration Statements are incorporated herein by reference.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8.        Exhibits


Exhibit No.
Description
4.1
Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on October 1, 2021)
4.2
Tenth Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on April 21, 2023)
5.1
Opinion of counsel*
23.1
Consent of Independent Registered Public Accounting Firm*
23.2
Consent of counsel (included in Exhibit 5.1)*
24.1
Power of Attorney (included on signature page)*
99.1
United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on June 27, 2025)
107.1
Filing Fee Table*

* Filed herewith

[SIGNATURES ON THE NEXT PAGE]
1


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Silver Spring, State of Maryland, on this 30th day of July, 2025.

UNITED THERAPEUTICS CORPORATION
By:
/s/ Martine A. Rothblatt
Martine A. Rothblatt, Ph.D.
Chairperson and Chief Executive Officer
        
POWER OF ATTORNEY


KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Martine A. Rothblatt, Ph.D., James C. Edgemond and Paul A. Mahon, and each of them, with full power of substitution and full power to act without the others, his or her true and lawful attorney-in-fact and agent, to act for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8, any and all amendments (including post-effective amendments) to this Registration Statement and any subsequent registration statement the Company may hereafter file with the Securities and Exchange Commission pursuant to Rule 462(b) under the Securities Act to register additional awards, and to file this Registration Statement and any subsequent registration statement and all amendments thereto, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do, and hereby ratifies and confirms all his or her said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in any number of counterparts, each of which shall constitute an original and all of which, taken together, shall constitute one Power of Attorney.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.

Name   Title   Date
     
/s/ Martine A. Rothblatt Chairperson and Chief Executive Officer
(Principal Executive Officer)		 July 30, 2025
Martine A. Rothblatt, Ph.D.
/s/ James C. Edgemond Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)		 July 30, 2025
James C. Edgemond
/s/ Christopher Causey Director July 30, 2025
Christopher Causey
2


 Director 
Raymond Dwek
/s/ Richard Giltner Director July 30, 2025
Richard Giltner
/s/ Ray Kurzweil Director July 30, 2025
Ray Kurzweil
/s/ Jan MalcolmDirectorJuly 30, 2025
Jan Malcolm
/s/ Linda MaxwellDirectorJuly 30, 2025
Linda Maxwell
/s/ Nilda MesaDirectorJuly 30, 2025
Nilda Mesa
/s/ Judy OlianDirectorJuly 30, 2025
Judy Olian
/s/ Christopher PatuskyDirectorJuly 30, 2025
Christopher Patusky

Director
Louis Sullivan
/s/ Tommy ThompsonDirectorJuly 30, 2025
Tommy Thompson


3

Source:

FAQ

How many new shares did UTHR register in the July 30 2025 S-8 filing?

950,000 common shares were registered for the Amended & Restated 2015 Stock Incentive Plan.

What is the total number of shares now registered under UTHR鈥檚 2015 Stock Incentive Plan?

Including this filing, the cumulative total is 14,770,000 shares.

Does the S-8 filing contain any earnings or financial statements for United Therapeutics?

No. The Form S-8 is limited to share registration and does not include financial results.

Who signed the Form S-8 on behalf of United Therapeutics?

Chairperson & CEO Martine A. Rothblatt, Ph.D., signed the filing on July 30 2025.

What filer status did United Therapeutics indicate in the S-8?

The company checked the box for Large Accelerated Filer.
Stock UTHR logo
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

#994 Ranked by Market Cap
N/A Ranked by Dividends

UTHR Latest News

Jul 30, 2025
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
Jul 16, 2025
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
Jun 24, 2025
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
Jun 23, 2025
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
Apr 30, 2025
United Therapeutics Corporation Reports First Quarter 2025 Financial Results

UTHR Latest SEC Filings

Jul 30, 2025
[8-K] United Therapeutics Corp Reports Material Event
Jul 30, 2025
[10-Q] United Therapeutics Corp Quarterly Earnings Report
Jul 25, 2025
[Form 4] United Therapeutics Corp Insider Trading Activity
Jul 24, 2025
[144] United Therapeutics Corp SEC Filing
Jul 14, 2025
[Form 4] United Therapeutics Corp Insider Trading Activity

UTHR Stock Data

13.42B
44.32M
1.83%
100.81%
5.49%
Biotechnology
Pharmaceutical Preparations
United States
SILVER SPRING